JP2014058509A5 - - Google Patents

Download PDF

Info

Publication number
JP2014058509A5
JP2014058509A5 JP2013169941A JP2013169941A JP2014058509A5 JP 2014058509 A5 JP2014058509 A5 JP 2014058509A5 JP 2013169941 A JP2013169941 A JP 2013169941A JP 2013169941 A JP2013169941 A JP 2013169941A JP 2014058509 A5 JP2014058509 A5 JP 2014058509A5
Authority
JP
Japan
Prior art keywords
oral
pharmaceutical
active ingredient
injection
suppository
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013169941A
Other languages
Japanese (ja)
Other versions
JP5857008B2 (en
JP2014058509A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2013169941A priority Critical patent/JP5857008B2/en
Priority claimed from JP2013169941A external-priority patent/JP5857008B2/en
Publication of JP2014058509A publication Critical patent/JP2014058509A/en
Publication of JP2014058509A5 publication Critical patent/JP2014058509A5/ja
Application granted granted Critical
Publication of JP5857008B2 publication Critical patent/JP5857008B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (2)

下記の式：The following formula:
Figure 2014058509
Figure 2014058509
 で示される化合物若しくはその塩、又はその水和物若しくはその溶媒和物を有効成分として含有し、経口錠剤、経口カプセル剤、経口散剤、経口顆粒剤、経口シロップ剤、皮下注射剤、筋肉内注射剤、静脈内注射剤、点滴剤、又は坐剤から選択される医薬組成物である感染症の予防及び／又は治療のために用いる医薬。Or a salt thereof, or a hydrate or solvate thereof as an active ingredient, oral tablet, oral capsule, oral powder, oral granule, oral syrup, subcutaneous injection, intramuscular injection A pharmaceutical used for the prevention and / or treatment of an infectious disease, which is a pharmaceutical composition selected from an agent, an intravenous injection, an infusion, or a suppository. 有効成分の投与量が１００〜１０００ｍｇ／日である、請求項１に記載の医薬。The pharmaceutical of Claim 1 whose dosage of an active ingredient is 100-1000 mg / day.

JP2013169941A 2012-08-20 2013-08-19 Medicament containing C-4 ″ substituted macrolide derivative Expired - Fee Related JP5857008B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013169941A JP5857008B2 (en) 2012-08-20 2013-08-19 Medicament containing C-4 ″ substituted macrolide derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012181339 2012-08-20
JP2012181339 2012-08-20
JP2013169941A JP5857008B2 (en) 2012-08-20 2013-08-19 Medicament containing C-4 ″ substituted macrolide derivative

Publications (3)

Publication Number Publication Date
JP2014058509A JP2014058509A (en) 2014-04-03
JP2014058509A5 true JP2014058509A5 (en) 2014-07-17
JP5857008B2 JP5857008B2 (en) 2016-02-10

Family

ID=50615337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013169941A Expired - Fee Related JP5857008B2 (en) 2012-08-20 2013-08-19 Medicament containing C-4 ″ substituted macrolide derivative

Country Status (1)

Country Link
JP (1) JP5857008B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102810A1 (en) 2014-08-18 2017-03-29 Taisho Pharmaceutical Co Ltd MACROLID DERIVATIVE REPLACED IN POSITION C-4
CN104592057B (en) * 2015-01-12 2017-05-10 中国科学院上海有机化学研究所 Synthesis method of trinitroethyl carbamate
WO2017142002A1 (en) * 2016-02-17 2017-08-24 大正製薬株式会社 Crystal forms of free c-4"-substituted macrolide compound and salt thereof, and production methods therefor
CN106748905B (en) * 2016-12-14 2018-04-13 河南省化工研究所有限责任公司 A kind of method for preparing 2 aminoethyl sulfanylamide hydrochlorides
CN106928294A (en) * 2017-03-22 2017-07-07 上海启雁实业有限公司 The method for preparing ketone lactone macrolide antibiotics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009978A1 (en) * 1996-09-04 1998-03-12 Abbott Laboratories 6-o-substituted ketolides having antibacterial activity
HN1998000074A (en) * 1997-06-11 1999-01-08 Pfizer Prod Inc DERIVATIVES FROM MACROLIDES C-4 SUBSTITUTED
WO2008143729A2 (en) * 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
AR085286A1 (en) * 2011-02-21 2013-09-18 Taisho Pharmaceutical Co Ltd MACROLIDO DERIVATIVE REPLACED IN POSITION C-4

Similar Documents

Publication Publication Date Title
JP2015078230A5 (en)
JP2016528301A5 (en)
JP2012255026A5 (en)
JP2016518337A5 (en)
JP2019516735A5 (en)
JP2016508134A5 (en)
JP2014221779A5 (en)
JP2020097577A5 (en)
IL295418B1 (en) B-d-2'-deoxy-2'a-fluoro-2'-b-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
JP2014058509A5 (en)
JP2016185995A5 (en)
JP2015057451A5 (en)
JP2014507446A5 (en)
JP2011068653A5 (en)
JP2016501828A5 (en)
JP2015500225A5 (en)
JP2016510326A5 (en)
JP2016505637A5 (en)
JP2015510916A5 (en)
JP2019526596A5 (en)
JP2015532296A5 (en)
JP2016539157A5 (en)
JP2015516419A5 (en)
JP2015521156A5 (en)
JP2014148552A5 (en)